Treatment of diffuse large B-cell lymphoma in the elderly: Strategies integrating oncogeriatric themes

Current Oncology Reports

Volumn 10, Issue 5, 2008, Pages 412-419

  Lugtenburg, Pieternella J ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; MITOXANTRONE; MONOCLONAL ANTIBODY; PIRARUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; FRAIL ELDERLY; FUNCTIONAL STATUS; GENE EXPRESSION PROFILING; GERIATRIC DISORDER; HERPES; HISTOPATHOLOGY; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; POLYNEUROPATHY; POPULATION RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION; AGED; AGING; FEMALE; GERIATRICS; MALE; METHODOLOGY; ONCOLOGY; PALLIATIVE THERAPY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMORBIDITY; FEMALE; GERIATRICS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDICAL ONCOLOGY; PALLIATIVE CARE; PROGNOSIS; TREATMENT OUTCOME;

EID: 55749094697     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0063-2     Document Type: Review

References (51)

1. Ries LA, Melbert D, Krapcho M, et al.: SEER cancer statistics review, 1975-2004. Available at http://seer.cancer.gov/csr/1975_2004/ results_merged/sect_19_nhl.pdf. Accessed August 2007.
2. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1997, 8: 973-978.
3. Gatter KC, Warnke RA: Diffuse large B-cell lymphoma. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Edited by Jaffe ES, Harris NL, Stein H, et al. Lyon: IARC Press; 2001:171-174.
4. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346: 1937-1947.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329: 987-994.
6. Pfreundschuh M, Schubert J, Ziepert M, et al.: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9: 105-116.
7. Berrios-Rivera JP, Fang S, Cabanillas ME, et al.: Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol 2007, 30: 163-171.
8. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, et al.: Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005, 41: 1051-1057.
9. Bairey O, Benjamini O, Blickstein D, et al.: Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol 2006, 17: 928-934.
10. Dixon DO, Neilan B, Jones SE, et al.: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 1986, 4: 295-305.
11. Sonneveld P, de Ridder M, van der Lelie H, et al.: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995, 13: 2530-2539.
12. Doorduijn JK, van der Holt B, van Imhoff GW, et al.: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003, 21: 3041-3050.
13. Tirelli U, Errante D, Van Glabbeke M, et al.: CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998, 16: 27-34.
14. Bastion Y, Blay JY, Divine M, et al.: Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival'a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997, 15: 2945-2953.
15. Bello C, Sotomayor EM: Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007, 2007: 233-242.
16. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346: 235-242.
17. Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23: 4117-4126.
18. Habermann TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24: 3121-3127.
19. Pfreundschuh M, Trumper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104: 634-641.
20. Wunderlich A, Kloess M, Reiser M, et al.: Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: Results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003, 14: 881-893.
21. Sonneveld P, van Putten WL, Biesma D, et al.: Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin's lymphoma in elderly patients [abstract]. Blood 2006, 108: 210a.
22. Ziepert M, Schmits R, Trumper L, et al.: Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma. Ann Oncol 2008, 19: 752-762.
23. Rueda A, Sabin P, Rifa J, et al.: R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: A multicentre, prospective study. Hematol Oncol 2008, 26: 27-32.
24. Rigacci L, Nassi L, Alterini R, et al.: Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: A pilot study. Acta Haematol 2006, 115: 22-27.
25. Brusamolino E, Rusconi C, Montalbetti L, et al.: Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: A phase II study of feasibility and toxicity. Haematologica 2006, 91: 496-502.
26. Aapro MS, Cameron DA, Pettengell R, et al.: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42: 2433-2453.
27. Lyman GH, Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98: 2402-2409.
28. Shayne M, Culakova E, Poniewierski MS, et al.: Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007, 110: 1611-1620.
29. Balducci L, Al-Halawani H, Charu V, et al.: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007, 12: 1416-1424.
30. Crawford J: Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia. Oncology (Williston Park) 2006, 20: 22-28.
31. Lyman GH: Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw 2005, 3: 557-571.
32. Smith TJ, Khatcheressian J, Lyman GH, et al.: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006, 24: 3187-3205.
33. Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003, 348: 2690-2691; discussion 2690-2691.
34. Pfreundschuh DM, Zeynalova S, Poeschel V, et al.: Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial if the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood 2007, 110: 789a.
35. Kolstad A, Holte H, Fossa A, et al.: Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007, 92: 139-140.
36. Wagner SA, Mehta AC, Laber DA: Rituximab-induced interstitial lung disease. Am J Hematol 2007, 82: 916-919.
37. Halaas JL, Moskowitz CH, Horwitz S, et al.: R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy. Leuk Lymphoma 2005, 46: 541-547.
38. Osterborg A, Steegmann JL, Hellmann A, et al.: Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol 2007, 136: 736-744.
39. Rizzo JD, Somerfield MR, Hagerty KL, et al.: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update. Blood 2008, 111: 25-41.
40. Bennett CL, Silver SM, Djulbegovic B, et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299: 914-924.
41. Solomon D, Sue Brown A, Brummel-Smith K, et al.: Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: Geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc 2003, 51: 1490-1494.
42. Wedding U, Rohrig B, Klippstein A, et al.: Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007, 133: 945-950.
43. de Groot V, Beckerman H, Lankhorst GJ, et al.: How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003, 56: 221-229.
44. Wedding U, Roehrig B, Klippstein A, et al.: Comorbidity in patients with cancer: Prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 2007, 61: 269-276.
45. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al.: A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: Prognostic impact independent of International Prognostic Index. Br J Haematol 2005, 129: 597-606.
46. Mori M, Kitamura K, Masuda M, et al.: Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol 2005, 81: 246-254.
47. Safra T, Muggia F, Jeffers S, et al.: Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000, 11: 1029-1033.
48. Zaja F, Tomadini V, Zaccaria A, et al.: CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006, 47: 2174-2180.
49. Sharpe M, Easthope SE, Keating GM, et al.: Polyethylene glycol-liposomal doxorubicin: A review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002, 62: 2089-2126.
50. Wildiers H, Highley MS, de Bruijn EA, et al.: Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003, 42: 1213-1242.
51. Balducci L, Extermann M: Management Af cancer in the older person: a practical approach. Oncologist 2000, 5: 224-237.